

Special Issue

Vectored Vaccines

Message from the Guest Editors

Vectored vaccines reached important milestones in term of safety and efficacy over the last decade. With the FDA approval in December 2019 of Erbevo, a recombinant Vesicular Stomatitis Virus-Vectored vaccine against Zaire Ebola Virus infection and China FDA approval in October 2017 of an Adenovirus-vectored Ebola vaccine established the regulatory baselines of two important recombinant vaccination platforms. This special issue will focus on bringing forward the most advanced research and development work on vectored vaccines from antigen design, immunogenicity, protection, manufacturing and delivery. Articles bringing novel perspectives on this broad topic are also welcome including recombinant viral vectors developed as immunotherapeutics or therapeutic vaccines.

Guest Editors

Prof. Dr. Amine A. Kamen

Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada

Prof. Dr. Olivier Henry

Department of Chemical Engineering, Polytechnique Montréal, Montréal, QC, Canada

Deadline for manuscript submissions

closed (31 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/55823

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).